Xiaomei Xue

Xiaomei Xue

Auto-generated profile, based on publicly available information

Xiaomei Xue

Affiliated Hospital of Qingdao University Qingdao China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
FYFei Yan
Fei Yan
XXXiaomei Xue
Xiaomei Xue
JLJie Lu
Jie Lu
NDNicola Dalbeth
Nicola Dalbeth
HQHan Qi
Han Qi
CLChanggui Li
Changgui Li
Objective: The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate‐lowering therapy (ULT) recommendation is first‐line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia. This comparative effectiveness clinical trial was undertaken to compare first‐line nontitrated low‐dose benzbromarone (LDBen) uricosuric therapy to XOI ULT with low‐dose febuxostat (LDFeb) in gout patients with renal uric acid underexcretion.Methods: We conducted a prospective, randomized, single‐center, open‐label trial in men with gout and renal uric acid underexcretion (defined as fractional excretion of urate <5.5% and uric acid excretion ≤600 mg/day/1.73 m2). A total of 196 participants were randomly assigned to receive LDBen 25 mg daily or LDFeb 20 mg daily for 12 weeks. All participants received daily urine alkalization with oral sodium bicarbonate. The primary end point was the rate of achieving the serum urate target of <6 mg/dl.Results: More participants in the LDBen group achieved the serum urate target than those in the LDFeb group (61% compared to 32%, P < 0.001). Rates of adverse events, including gout flares and urolithiasis, did not differ between groups, with the exception of greater transaminase elevation in the LDFeb group (4% for LDBen compared to 15% for LDFeb, P = 0.008).Conclusion: Compared to LDFeb, LDBen has superior urate‐lowering efficacy and similar safety in treating relatively young and healthy patients with renal uric acid underexcretion–type gout.

11 March 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JLJie Lu
Jie Lu
YHYuwei He
Yuwei He
RTRobert Terkeltaub
Robert Terkeltaub
MSMing-Shu Sun
Ming-Shu Sun
ZRZijing Ran
Zijing Ran
CLChanggui Li
Changgui Li
Objectives COVID-19 vaccination often triggers a constellation of transitory inflammatory symptoms. Gout is associated with several comorbidities linked to poor outcomes in COVID-19, and gout flares can be triggered by some vaccinations. We analysed the risk of gout flares in the first 3 months after COVID-19 vaccination with inactivated virus, and whether colchicine can prevent gout flares following post-COVID-19 vaccination. Methods A clinical delivery population-based cross-sectional study was conducted in the Gout Clinic at the Affiliated Hospital of Qingdao University between February and October 2021. Study participants were selected using a systematic random sampling technique among follow-up patients with gout. We collected data, including vaccinations and potential risk factors, using a combination of interviews, health QR codes and medical records. Logistic regression was used to adjust for covariates. Results We enrolled 549 gout participants (median age 39 years, 84.2% vaccinated). For the 462 patients who received COVID-19 vaccine, 203 (43.9%) developed at least one gout flare in the 3 months after vaccination. Most of these flares were experienced within 1 month after the first (99/119 (83.2%)) or second (70/115 (60.9%)) dose of vaccine. Compared with unvaccinated participants, COVID-19 vaccination was associated with higher odds of gout flare within 3 months (adjusted OR 6.02; 95% CI 3.00 to 12.08). Colchicine use was associated with 47% less likelihood of postvaccine gout flare. Conclusion COVID-19 vaccination was associated with increased odds of gout flare, which developed mainly in month 1 after each vaccine dose, and was negatively associated with colchicine prophylaxis.

27 March 2024 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
HQHan Qi
Han Qi
MSMingshu Sun
Mingshu Sun
RTRobert Terkeltaub
Robert Terkeltaub
Tony R. MerrimanTony R. Merriman
Tony R. Merriman
HCHaibing Chen
Haibing Chen
CLChanggui Li
Changgui Li

10 August 2009 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
SZS.-H. Zhao
S.-H. Zhao
YCY.-L. Chu
Y.-L. Chu
DCD.-X. Cheng
D.-X. Cheng
AWAhmed Bilal Waqar
Ahmed Bilal Waqar
QYQi Yu
Qi Yu
ELEnqi Liu
Enqi Liu
Introduction: Virological responses to interferon (IFN) treatment for chronic hepatitis C (CHC) have been found to be correlated with racial differences. Furthermore, higher sustained virological response (SVR) rates were obtained in many randomised clinical trials (RCT) in Caucasian patients with CHC after treating with peg‐IFN than those with IFN. However, it is not clear whether this conclusion can be adapted to patients of Chinese descent. Methods: A search of MEDLINE and China National Knowledge Infrastructure between 1966 and 2008 was performed. Trials comparing the use of peg‐IFN plus ribavirin vs. IFN plus ribavirin in treating Chinese patients with CHC were assessed. Results: Of the 94 studies screened, seven RCTs including 398 patients (peg‐IFN therapy 232, IFN therapy 166) were analysed. The SVRs obtained in patients treated with peg‐IFN plus ribavirin were significantly higher than in patients treated with IFN plus ribavirin [70% vs. 35%, relative risk, 1.76; 95% confidence interval: 1.21–2.56; p (0.01)]. Withdrawal rates were similar between patients treated with peg‐IFN plus ribavirin and IFN plus ribavirin. Conclusion: Chinese patients with CHC also have a greater likelihood of achieving an SVR with peg‐IFN plus ribavirin.

20 February 2024 in Arthritis Care & Research
Verified
Journal Article
Closed access
XXXiaomei Xue
Xiaomei Xue
MSMingshu Sun
Mingshu Sun
FYFei Yan
Fei Yan
NDNicola Dalbeth
Nicola Dalbeth
YHYuwei He
Yuwei He
CLChanggui Li
Changgui Li

28 August 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
AJAichang Ji
Aichang Ji
YSYang Sui
Yang Sui
XXXiaomei Xue
Xiaomei Xue
XJXiapeng Ji
Xiapeng Ji
WSWenrui Shi
Wenrui Shi
CLChanggui Li
Changgui Li
Objective: Mechanisms underlying the adolescent‐onset and early‐onset gout are unclear. This study aimed to discover variants associated with early‐onset gout.Methods: We conducted whole‐genome sequencing in a discovery adolescent‐onset gout cohort of 905 individuals (gout onset 12 to 19 years) to discover common and low‐frequency single‐nucleotide variants (SNVs) associated with gout. Candidate common SNVs were genotyped in an early‐onset gout cohort of 2,834 individuals (gout onset ≤30 years old), and meta‐analysis was performed with the discovery and replication cohorts to identify loci associated with early‐onset gout. Transcriptome and epigenomic analyses, quantitative real‐time polymerase chain reaction and RNA sequencing in human peripheral blood leukocytes, and knock‐down experiments in human THP‐1 macrophage cells investigated the regulation and function of candidate gene RCOR1.Results: In addition to ABCG2, a urate transporter previously linked to pediatric‐onset and early‐onset gout, we identified two novel loci (Pmeta < 5.0 × 10−8): rs12887440 (RCOR1) and rs35213808 (FSTL5‐MIR4454). Additionally, we found associations at ABCG2 and SLC22A12 that were driven by low‐frequency SNVs. SNVs in RCOR1 were linked to elevated blood leukocyte messenger RNA levels. THP‐1 macrophage culture studies revealed the potential of decreased RCOR1 to suppress gouty inflammation.Conclusion: This is the first comprehensive genetic characterization of adolescent‐onset gout. The identified risk loci of early‐onset gout mediate inflammatory responsiveness to crystals that could mediate gouty arthritis. This study will contribute to risk prediction and therapeutic interventions to prevent adolescent‐onset gout.